Development and Validation of New Analytical Method for the Determination of Particle Size Distribution in Empagliflozin Using Laser-Based Particle Size Analyzer
Abstract
This paper describes a rugged and precise analytical method developed and validated for determining the particle size distribution of Empagliflozin drug substance using a wet dispersion technique on the Malvern Mastersizer 3000. The method was optimized to achieve uniform dispersion and reproducible measurements of particle size parameters (D10, D50, D90). Validation of the method was carried out in accordance with ICH Q2(R2) guideline and demonstrated satisfactory results for precision, intermediate precision, and robustness. All validation parameters were found within the predefined acceptance criteria, confirming the reliability of the procedure. Hence, the developed method is suitable for particle size analysis of Empagliflozin active pharmaceutical ingredient (API).
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.